In the U.S. alone, more than $100 billion a year is spent treating the more than six million children diagnosed with attention-deficit/hyperactivity disorder (ADHD). An international team, led by researchers from The Ohio ...
Oct 21, 2014
0
0
The risk of developing cancer in a salivary gland might be higher in people with mutations in either of two genes associated with breast and ovarian cancer, according to a new study by researchers at The Ohio State University ...
Oct 8, 2014
0
0
A molecule that helps cancer cells evade programmed self-destruction, an internal source of death, might also help malignant cells hide from the immune system, an external source of death.
Oct 7, 2014
0
0
(Medical Xpress)—Researchers have developed two new anticancer peptide vaccines and two peptide inhibitors as part of a larger peptide immunotherapy effort led by investigators at The Ohio State University Comprehensive ...
Sep 24, 2014
0
0
Cardiovascular researchers at The Ohio State University Wexner Medical Center have successfully used a protein known as MG53 to treat acute and chronic lung cell injury. Additionally, application of this protein proved to ...
Jul 24, 2014
0
1
Giving low doses of a particular targeted agent with a cancer-killing virus might improve the effectiveness of the virus as a treatment for cancer, according to a study led by researchers at The Ohio State University Comprehensive ...
Jun 16, 2014
0
1
Researchers have taken the next step in confirming the identity of previously unknown gene mutation that drives lung cancer development. Scientists at The Ohio State University Comprehensive Cancer Center – Arthur G. James ...
Jun 13, 2014
0
0
(Medical Xpress)—The Ohio State University and the University of Michigan have signed an exclusive worldwide agreement with Ohio-based Venture Therapeutics, Inc, to form a new company to develop and commercialize a pharmaceutical ...
Jun 6, 2014
0
0
In a head-to-head comparison of two Food and Drug Administration-approved drugs for the treatment of relapsed chronic lymphocytic leukemia (CLL), ibrutinib significantly outperformed ofatumumab as a second-line therapy, according ...
May 31, 2014
0
0
A new study by researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) provides evidence that genetically modifying ...
May 12, 2014
0
0
